Becton, Dickinson and Company (NYSE:BDX) Plans Quarterly Dividend of $1.04

Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Thursday, November 7th,RTT News reports. Shareholders of record on Monday, December 9th will be given a dividend of 1.04 per share by the medical instruments supplier on Tuesday, December 31st. This represents a $4.16 annualized dividend and a yield of 1.89%. The ex-dividend date of this dividend is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95.

Becton, Dickinson and Company has raised its dividend by an average of 4.8% annually over the last three years and has increased its dividend every year for the last 53 years. Becton, Dickinson and Company has a payout ratio of 28.8% meaning its dividend is sufficiently covered by earnings. Analysts expect Becton, Dickinson and Company to earn $15.68 per share next year, which means the company should continue to be able to cover its $4.16 annual dividend with an expected future payout ratio of 26.5%.

Becton, Dickinson and Company Stock Down 1.0 %

Becton, Dickinson and Company stock opened at $220.02 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89. The firm’s fifty day simple moving average is $233.03 and its 200-day simple moving average is $233.73. The company has a market capitalization of $63.61 billion, a P/E ratio of 37.04, a P/E/G ratio of 1.65 and a beta of 0.41.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.42 earnings per share. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Buy” and a consensus target price of $283.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.